IQVIA Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $16.6B+8.0% YoYTTM through 31 Mar 2026
Net Income $1.4B+0.9% YoYTTM through 31 Mar 2026
Free Cash Flow $2.1BTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 20.2% |
| Operating Margin | 13.2% |
| Net Margin | 8.3% |
Returns
22.3%ROE
4.7%ROA
6.9%ROIC
Balance Sheet Health
Debt / Equity2.55x
Current Ratio0.75x
Net Debt$13.9B
Cash & Equivalents$1.9B
Quality Metrics
Altman Z-Score2.23
Piotroski F-Score6 / 9
FCF Margin12.7%
Rule of 4017.4
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $16.3B
Diluted EPS$8.05TTMFY2025: $7.84
Dividend
No dividend
Capital Allocation
Capex Intensity3.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Technology & Analytics Solutions | $6.6B | +7.6% | View detailsEffective January 1, 2026, this segment is renamed Commercial Solutions and incorporates the CSMS segment, while transferring certain Real-World offerings to R&DS. |
| Research & Development Solutions | $8.9B | +4.3% | View detailsEffective January 1, 2026, certain Real-World offerings representing $674 million in 2025 revenue are transferred into this segment from TAS. |
| Contract Sales & Medical Solutions | $788M | +9.8% | View detailsEffective January 1, 2026, this segment is fully incorporated into the Technology & Analytics Solutions segment (renamed Commercial Solutions). |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.